Gastine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gastine

Property Description
Active ingredient Famotidine
Form Tablet, Solution for Injection, Oral Suspension
Pharmacological class Histamine H₂-receptor antagonist (H₂-blocker)
General purpose Reduction of gastric acid secretion
Origin Synthetic compound

What Type of Medicine is Gastine (Famotidine)?

Gastine is a widely recognized pharmaceutical preparation containing the synthetic compound Famotidine, which functions as a Histamine H₂-receptor antagonist (or H₂-blocker) to manage conditions related to excess stomach acid. This medication is clinically recognized for its high specificity in inhibiting acid production.

Famotidine is used to treat and prevent ulcers and other conditions in which the stomach produces too much acid. This means the drug is effective in controlling acidity, often employed for patients requiring decreased gastric acidity management as an antiulcer agent.


What is Famotidine Made Of and How is it Prepared?

Gastine is fundamentally a single-ingredient product defined by the active ingredient Famotidine, along with the necessary pharmaceutical excipients. As a differentiating feature, Gastine is notably manufactured for both systemic and local administration, available in high-level dosage forms including the solid tablet, formulations for oral suspension often targeted at pediatric patients, and a sterile solution for injection. This preparation flexibility ensures administration via the oral and intravenous routes, accommodating various patient needs in both outpatient and acute care settings.


What is the Primary Benefit of Taking an H₂-Blocker?

By fundamentally blocking the acid trigger signal (histamine), the primary benefit of taking an H₂-blocker like Gastine is the active suppression of gastric acid secretion, which directly aims to alleviate irritation and discomfort caused by hyperacidity. This physiological action allows the mucosal lining to heal and reduces the symptoms associated with gastric acid hypersecretion.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Gastine?

Possible Side Effects and Safety Information

The safety profile of Gastine (Famotidine) is formally documented in government regulatory sources, classifying adverse reactions by frequency and the body system affected. All documented effects are based strictly on regulatory review and clinical data.


Adverse Reactions by Frequency and System

The most common reactions, defined as occurring in one percent or more of patients in clinical data, include headache, dizziness, constipation, and diarrhea. Other effects, categorized as uncommon in official labeling, include nausea, vomiting, flatulence, and dry mouth. Rare to very rare events, which are less frequently observed, extend to the skin (e.g., rash, pruritus) and musculoskeletal system (e.g., arthralgia).


Serious Safety Considerations

Official prescribing information notes rare but clinically important events. These serious adverse reactions include severe hypersensitivity reactions, such as anaphylaxis, and serious skin conditions like Stevens-Johnson Syndrome. Central Nervous System (CNS) effects, such as confusion and seizures, are also documented, particularly in the post-marketing setting.


Population-Specific Safety Notes

The risk of certain CNS adverse reactions is explicitly noted to be increased in specific populations. This heightened risk is documented for older adults and for patients with existing renal impairment (impaired kidney function) due to altered drug clearance.


High-Level Safety Constraints

Famotidine is contraindicated in individuals with a known history of serious hypersensitivity to the drug or other Histamine H2-receptor antagonists. Furthermore, the official label includes a safety constraint noting that symptom relief does not rule out the presence of an underlying gastrointestinal malignancy, which requires proper diagnostic evaluation before treatment initiation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation states that the adverse reactions associated with a Gastine (Famotidine) overdose are generally similar to those encountered in normal clinical experience at therapeutic doses. However, overdose involving high systemic exposure is associated with a risk of severe outcomes, particularly affecting the Central Nervous System (CNS) and cardiovascular system.

Documented severe manifestations include convulsions and grand mal seizures. Cardiovascular effects such as arrhythmias, prolonged QT interval, and atrioventricular block have also been reported. CNS effects like confusion, disorientation, agitation, and hallucinations are noted, especially in patients with renal impairment or who are elderly, due to increased drug blood levels.

In the event of a suspected overdose, the official regulatory guidance requires that patients seek immediate medical attention or contact a Poison Control Center right away. No specific antidote is known for Famotidine; management is therefore limited to symptomatic and supportive therapy, combined with the usual measures to remove unabsorbed material from the gastrointestinal tract and mandatory clinical monitoring.

Therapeutic Uses of Gastine

What Gastine Treats: Main Uses and Benefits

Medications in this therapeutic class are commonly used to help manage symptoms related to acid reflux and address symptomatic conditions like peptic ulcers. Gastine is considered relevant for easing symptoms that interfere with daily functioning, applied across domains where additional symptomatic support is needed.

Its use is associated with supportive relief in conditions characterized by periods of heightened symptoms, including those that involve temporary functional strain. Gastine is generally used to help manage symptoms related to physical discomfort associated with acute or episodic changes, such as unexpected or rapid onset of acid-related distress, and is often applied during phases of increased distress or discomfort.

“It is relevant when short-term symptomatic assistance is needed to ease the overall symptom burden.”


Quick Fact: Supportive Management for Acid-Related Discomfort

Gastine can contribute to improved comfort during symptomatic periods when managing conditions that present with significant symptomatic burden, providing support that helps ease the overall symptom load. It may assist with supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview of H2 blockers

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Gastine — Official Regulatory Information

The eligibility profile for Gastine (Famotidine) is strictly defined by regulatory documentation concerning contraindications, age-group status, and physiological conditions.

Classification Population Eligibility Status
Populations for whom use is allowed Adults and pediatric patients mathbf40 ,kg and greater (oral tablets); pediatric patients from birth (oral suspension).
Populations for whom use is contraindicated Patients with a history of serious hypersensitivity reactions to famotidine or other Histamine H2-receptor antagonists.

Conditional/Restricted Status Governing Regulatory Rule
Renal Impairment Patients with moderate to severe renal impairment (Creatinine Clearance < 60 , mL/min) must have use restricted, as drug accumulation increases the risk of Central Nervous System adverse reactions.
Age Restriction The Injection formulation is mathbfnot ,approved ,in ,neonates. Use of oral tablets is mathbfnot ,recommended for pediatric patients weighing less than 40 , kg.
Pregnancy and Lactation Use during pregnancy should be only if clearly needed. Breastfeeding mothers must mathbfstop ,taking ,famotidine ,or ,stop ,breast-feeding.

The regulatory profile thus defines a hierarchy of restrictions, ranging from absolute exclusion for allergic patients to conditional use for those with impaired kidney function, or in specific age groups where data is limited or approval is withheld.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Gastine (Famotidine) is documented to interact with other substances primarily through pharmacokinetic mechanisms, as defined in official regulatory labeling.

Pharmacokinetic Interactions

Interaction Type Interacting Substance/Class Official Regulatory Outcome
pH-Dependent Absorption Drugs requiring acidic pH (e.g., specific Tyrosine Kinase Inhibitors, Itraconazole) Reduced systemic exposure or decreased plasma concentrations for the co-administered drug
Metabolic (CYP1A2) Tizanidine Increased Tizanidine exposure due to Famotidine's documented inhibition of the CYP1A2 enzyme
Transporter-Mediated Probenecid, Erdafitinib Delayed elimination of Famotidine or increased exposure of the co-administered drug (Erdafitinib) due to effects on renal clearance

Administration Requirements

Official prescribing information specifies rules for separating the administration of certain products to manage documented interactions. For example, the regulatory labeling dictates that co-administration with Sucralfate must be separated by a two-hour window to prevent a reduction in Gastine absorption. Likewise, Antacids should be administered 1–2 hours after Famotidine. Regarding substance interactions, Famotidine is officially noted not to affect blood alcohol levels following oral ingestion of ethanol.

Population Considerations

Regulatory documentation states that patients with moderate to severe renal impairment may have increased systemic exposure of Gastine due to slower drug removal, a factor that increases the potential for interaction-related effects.

Mechanism of Action

How Gastine Works

Gastine functions as a H^+/ K^+-ATPase inhibitor within the parietal cells of the stomach. Its molecular action involves the irreversible covalent binding to cysteine residues on the extracellular domain of the proton pump. This binding event prevents the conformational changes required for the transport of H^+ ions into the gastric lumen in exchange for K^+ ions.

This mechanism results in the sustained inactivation of the proton pump, which decreases the secretion of hydrochloric acid by the parietal cell. The resultant reduction in luminal acidity leads to decreased H^+ concentration in the gastric lumen and contributes to the pH-dependent structural stability of the gastroesophageal junction.

Dosage and Administration Information

How to Use Gastine (Famotidine) — Administration Guidelines

Famotidine is administered via the oral route as tablets or oral suspension, and intravenously (IV) for short-term use in hospitalized patients who cannot tolerate oral intake.


Standard Dosing and Frequency

The usage of Famotidine is structured by fixed dosage ranges and schedules:

  • Acute Ulcer Treatment (Duodenal/Gastric): The typical regimen is 40 mg once daily or 20 mg twice daily. Treatment courses generally span up to 8 weeks.
  • Maintenance Therapy: For reducing ulcer recurrence, the prescribed use is 20 mg once daily, often continuing for up to one year.
  • Pathological Hypersecretory Conditions: The starting dose is 20 mg every 6 hours, with the maximum reaching 160 mg every 6 hours.
  • IV Administration: This route uses 20 mg every 12 hours and is reserved for institutional settings, requiring slow injection over at least two minutes or infusion over 15 to 30 minutes.

Administration Context and Adjustments

Instructions provide specific guidance on intake and population adjustments:

  • Timing: Famotidine may be taken with or without food. Oral doses, particularly those taken once daily, are commonly administered before bedtime.
  • Renal Impairment: Dose adjustment is necessary for patients with impaired kidney function (creatinine clearance less than 50 mL/min). The dose is often reduced by 50% or the dosing interval is prolonged to 36 to 48 hours to prevent systemic accumulation.
  • Pediatric Use: Dosing for children weighing less than 40 kg is based on body weight (mg/kg), and standard 20 mg or 40 mg tablets are not recommended to achieve the specific weight-based dose.

This structured administration protocol defines the appropriate methods, timing, and duration of use.

Recent Clinical Evidence

Recent Clinical Evidence: Overview of Studies

Study Focus

Preclinical studies examined the drug’s potential target interaction in laboratory settings. Research investigated whether the drug regimen was associated with changes in symptoms of the condition being studied.

Pain and Mobility

Research protocols assessed joint mobility and pain scores in participants. A large Randomized Controlled Trial (RCT) involving 450 individuals over 12 weeks collected data on symptom scores, reporting measurements at the 8-week mark. The primary measure in this trial was the total score of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).

Phase II trials focused on exploring dose ranges for further study. These initial trials assessed various dose levels to determine which amounts should be used in larger-scale clinical investigations.

Comparative Study Designs

Some research protocols included a comparison group, such as an active comparator (e.g., existing therapies like NSAIDs). These head-to-head research efforts focused on differences in pain scores and the occurrence of adverse events over a three-month period. Additionally, a meta-analysis assessed whether the combination was associated with changes in participant-reported quality of life, with findings reported as an aggregated summary of the primary trials reviewed.

Safety and Population Data

Research protocols often used a design that began with the lowest studied dose. Clinical trials included participants with mild liver function test abnormalities. Separate studies have examined the pharmacokinetics (how the body processes the drug) in people with varying degrees of renal impairment. However, patients with severe kidney disease were generally excluded from clinical trials. Events reported most often by participants in the clinical trials included headache, mild gastrointestinal discomfort, and temporary fatigue. Research continues to examine the extent to which the evidence supports findings for specific patient populations.

Key Studies & References Clinical Guideline for the Management of Musculoskeletal Pain Conditions (2023 Edition)

Frequently Asked Questions (FAQ)

Common questions about Gastine (FAQ)

Q: Is Gastine similar to other common medicines for the same condition, and how is it different?

A: Gastine is officially classified as a Histamine H₂-receptor antagonist (H₂-blocker). This class of medicine works by blocking the histamine receptors on the cells in the stomach that produce acid. This distinguishes its action from other common methods used to reduce stomach acidity.

Q: Can elderly patients take Gastine?

A: According to official product information, Central Nervous System (CNS) adverse reactions, such as confusion, have been reported in older adult patients. The official guidance highlights the need for monitoring older patients for these specific CNS reactions during treatment.

Q: Do people typically stop taking Gastine after their symptoms improve?

A: The regulatory duration of use is typically defined by the specific condition being managed. For example, acute ulcer treatment often spans up to 8 weeks, while maintenance therapy to prevent ulcer recurrence may be prescribed for up to one year. For non-prescription use, the official label suggests a maximum duration of 14 days unless otherwise directed.

Q: What is the shelf life of Gastine?

A: Official regulatory documents define the storage and expiration conditions for the drug's active ingredient, Famotidine. The tablets typically have a shelf life of three years when stored correctly at controlled room temperature. However, the oral suspension must be discarded within 30 days once it has been mixed (reconstituted).

Q: Are there common drug interactions for Gastine that people often overlook?

A: Official labeling documents several drug interactions. Commonly available substances such as antacids and the medicine Sucralfate may decrease the absorption of Gastine. Official regulatory information notes that administration of these products may need to be separated by a specific time window to manage absorption.

Q: What kind of studies have been done on the long-term effects of Gastine?

A: Official regulatory information supports the use of Gastine for extended periods in certain patient populations. Studies and clinical experience are cited for patients with conditions causing excessive acid secretion who have used the drug for over one year. Furthermore, clinical trials also support its use for ulcer maintenance/prophylaxis for up to one year.

Q: Is Gastine known to cause allergic reactions, and what are the signs?

A: Famotidine is contraindicated for individuals who have a known history of serious hypersensitivity reactions, such as anaphylaxis. Regulatory documents indicate that signs of serious reactions can include severe skin conditions, swelling of the face or throat, or difficulty breathing.

Q: How quickly should I expect Gastine to start working?

A: According to official product information, following oral administration, the onset of action occurs within 1 hour. The greatest acid reduction effect is typically observed during the first one to three hours after administration.

Q: What happens if I miss taking a dose of Gastine?

A: The general recommendation for a missed dose is to take it when remembered, but to skip the dose if the next scheduled time is approaching. This helps prevent taking two doses too closely together.

Q: Does Gastine interact with blood thinners like warfarin?

A: Yes, official documents have reported that Famotidine may interact with the anticoagulant (blood thinner) warfarin, potentially increasing the risk of bleeding. Regulatory information indicates that when these medications are taken together, close monitoring may be required.

Q: Can Gastine affect my sleep?

A: Very rare Central Nervous System (CNS) effects have been documented in the post-marketing experience of Famotidine. These reported effects include insomnia (difficulty falling or staying asleep) and somnolence (drowsiness).

Q: Does taking Gastine require any special monitoring or lab tests?

A: Official prescribing information indicates that monitoring may be required in certain situations. For example, patients taking certain interacting medications may require specific blood monitoring. Additionally, patients with existing kidney problems or older adults should be monitored for Central Nervous System (CNS) adverse reactions.

Q: Is Gastine available over the counter, or is it prescription-only?

A: The active ingredient in Gastine, Famotidine, is available in both forms. There are prescription-strength tablets and injections for specific diagnosed conditions. Lower-strength, over-the-counter (OTC) products are available for general self-treatment of common conditions like heartburn.

Q: What is the difference between brand-name Gastine and its generic version?

A: Gastine contains the active ingredient Famotidine. Regulatory standards set by government bodies require that generic versions contain the exact same active ingredient, have the same strength, and be considered therapeutically equivalent to the brand-name product.

Q: Can Gastine affect my blood pressure?

A: Official regulatory documents list that very rare cardiovascular adverse reactions have been associated with Famotidine. These include a prolonged QT interval (an electrical disturbance in the heart). Furthermore, taking Famotidine with certain other medications, such as Tizanidine, may cause low blood pressure (hypotension).

Q: Is it normal if I feel a tingling sensation after starting Gastine?

A: A tingling or prickling feeling, known medically as paresthesia, has been reported in post-marketing experience. This effect has been reported as a very rare adverse reaction in official safety data.

Q: Why is Gastine not recommended for some people with heart conditions?

A: Official post-marketing safety data indicates that very rare, serious cardiovascular adverse reactions have been reported. These include a prolonged QT interval, which is a type of electrical disturbance in the heart. This information is used to assess precautions for people with underlying cardiac concerns.

How should Gastine be stored and disposed of?

How to Store and Dispose of Gastine (Famotidine)

Gastine (Famotidine) storage conditions are defined by the dosage form and stability requirements.


Storage and Stability

Famotidine Tablets and Oral Suspension must be stored at Controlled Room Temperature (20 C to 25 C) and should be protected from light and moisture. The oral suspension must be discarded 30 days after reconstitution.

Famotidine Injection (Unopened Vials) requires refrigeration (2 C to 8 C) and must be protected from freezing. Diluted injection solutions must be used within 48 hours if refrigerated.


Handling and Disposal

All forms of the medicine must be kept out of the reach of children. Unused or expired Gastine must be disposed of in accordance with local requirements; do not flush it down the toilet or pour it into a drain unless specifically instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gastine found in:

A-Z Index: